From Financial Modeling Prep: 2025-01-22 08:45:00

Johnson & Johnson (NYSE:JNJ) exceeded expectations in Q4, driven by strong demand for cancer treatments and acquisitions. The company projects 2025 sales of $90.9 billion to $91.7 billion and adjusted EPS of $10.75 to $10.95, above analyst estimates. Revenue rose 5.3% to $22.52 billion, with oncology drug sales up 19%.

Darzalex, a multiple myeloma therapy, saw sales increase by nearly 21% to over $3 billion. The recent acquisition of Shockwave Medical added $258 million to quarterly revenue, boosting overall performance. Adjusted earnings for the quarter were $2.04 per share, beating analyst expectations despite a slight decrease from the previous year.

An impairment charge of $0.22 related to the V-Wave acquisition impacted earnings, but JNJ still outperformed projections. The company remains optimistic about its future growth prospects, with a strong pipeline of products and strategic acquisitions driving its success.



Read more at Financial Modeling Prep:: Johnson & Johnson Exceeds Q4 Expectations with Str…